Visit https://www.peervoice.com/RJT860 to view the entire programme with slides. After completing “Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?”, participants will be able to: Explain the unmet medical needs in diffuse large B-cell lymphoma (DLBCL); Assess the latest clinical data for novel and emerging antibody strategies for the treatment of relapsed/refractory DLBCL; Translate available clinical data for immunotherapeutic strategies into practical guidance for the clinic in order to maximise patient outcomes.